Dwight Schroeder, MD
Psychiatry · Cedar Rapids, IANPI 1528047081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 1,015 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,589, 2.5 times the $1,031 reported in 2019. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,015 payments — averaging $12.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$837
- plus $5K from 26 others
What the payments were for
- Food & beverage$12,520100%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 105 | $1,614 |
| AbbVie(2 entities) | 252 | $1,602 |
| Alkermes, Inc. | 89 | $1,346 |
| Neurocrine Biosciences, Inc. | 142 | $1,121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,001 |
| Teva Pharmaceuticals USA, Inc. | 51 | $837 |
| Lundbeck LLC | 58 | $772 |
| Supernus Pharmaceuticals, Inc. | 26 | $679 |
| Sunovion Pharmaceuticals Inc. | 29 | $447 |
| Johnson & Johnson | 31 | $447 |
| Ironshore Pharmaceuticals Inc. | 22 | $367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $331 |
| Corium, LLC | 16 | $265 |
| Vanda Pharmaceuticals Inc. | 12 | $235 |
| Axsome Therapeutics, Inc. | 13 | $233 |
| Almatica Pharma LLC | 11 | $187 |
| E.r. Squibb & Sons, L.L.C. | 12 | $182 |
| Jazz Pharmaceuticals Inc. | 11 | $182 |
| Harmony Biosciences LLC | 8 | $132 |
| Merck | 5 | $82 |
| Bausch Health US, LLC | 4 | $76 |
| Indivior Inc. | 4 | $76 |
| Vertical Pharmaceuticals, LLC | 5 | $74 |
| Collegium Pharmaceutical, Inc. | 4 | $59 |
| Shire North American Group Inc | 4 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Alfasigma USA, Inc. | 1 | $24 |
| Eisai Inc. | 2 | $24 |
| Tris Pharma Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Neuronetics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$303
How this compares
$12,572 in reported general payments places this provider in the 95th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 22 | $31,487 |
| FetzimaLevomilnacipran Hcl | 13 | $9,305 |
| Lisdexamfetamine Dimesylate | 20 | $5,525 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $4,388 |
| Dextroamphetamine Sulfate | 33 | $4,241 |
| Duloxetine Hcl | 135 | $4,040 |
| Methylphenidate Hcl | 112 | $3,758 |
| Aripiprazole | 59 | $2,624 |
| Doxepin Hcl | 58 | $2,497 |
| Bupropion XlBupropion Hcl | 118 | $2,333 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 58 | $2,236 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,844 |
| Vilazodone Hcl | 16 | $1,816 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $1,805 |
| Trazodone Hcl | 142 | $1,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,614 | $31,48722 claims |
| AbbVieFetzima | $1,602 | $9,30513 claims |
| Almatica Pharma LLCSertraline Hcl | $187 | $78575 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Cedar Rapids
- Alan WhittersCedar Rapids$170K
- Jacob MillerCedar Rapids$2K
- Jeffrey WilharmCedar Rapids$2K
- Allyson WheatonCedar Rapids$2K
- Rebecca WolfeCedar Rapids$1K
- Frank BabcockCedar Rapids$1K
- Sundara Rameshwar Munagala VenkataCedar Rapids$867
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.